These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

193 related articles for article (PubMed ID: 21737325)

  • 1. Response to rituximab in 3 children with opsoclonus-myoclonus syndrome resistant to conventional treatments.
    Battaglia T; De Grandis E; Mirabelli-Badenier M; Boeri L; Morcaldi G; Barabino P; Intra C; Naselli F; Pistoia V; Veneselli E; Conte M
    Eur J Paediatr Neurol; 2012 Mar; 16(2):192-5. PubMed ID: 21737325
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Neuroepidemiologic trends in 105 US cases of pediatric opsoclonus-myoclonus syndrome.
    Tate ED; Allison TJ; Pranzatelli MR; Verhulst SJ
    J Pediatr Oncol Nurs; 2005; 22(1):8-19. PubMed ID: 15574722
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Rituximab for treatment of opsoclonus-myoclonus syndrome in neuroblastoma.
    Burke MJ; Cohn SL
    Pediatr Blood Cancer; 2008 Mar; 50(3):679-80. PubMed ID: 16900484
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Rituximab and intravenous immunoglobulins for relapsing postinfectious opsoclonus-myoclonus syndrome.
    Leen WG; Weemaes CM; Verbeek MM; Willemsen MA; Rotteveel JJ
    Pediatr Neurol; 2008 Sep; 39(3):213-7. PubMed ID: 18725071
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Improvement of neurological status and quality of life in children with opsoclonus myoclonus syndrome at long-term follow-up.
    Catsman-Berrevoets CE; Aarsen FK; van Hemsbergen ML; van Noesel MM; Hakvoort-Cammel FG; van den Heuvel-Eibrink MM
    Pediatr Blood Cancer; 2009 Dec; 53(6):1048-53. PubMed ID: 19672966
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Chronic relapsing opsoclonus-myoclonus syndrome: combination of cyclophosphamide and dexamethasone pulses.
    Wilken B; Baumann M; Bien CG; Hero B; Rostasy K; Hanefeld F
    Eur J Paediatr Neurol; 2008 Jan; 12(1):51-5. PubMed ID: 17625938
    [TBL] [Abstract][Full Text] [Related]  

  • 7. CCR7 signaling in pediatric opsoclonus-myoclonus: upregulated serum CCL21 expression is steroid-responsive.
    Pranzatelli MR; Tate ED; McGee NR; Ransohoff RM
    Cytokine; 2013 Oct; 64(1):331-6. PubMed ID: 23764550
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rituximab (anti-CD20) adjunctive therapy for opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Travelstead AL; Barbosa J; Bergamini RA; Civitello L; Franz DN; Greffe BS; Hanson RD; Hurwitz CA; Kalinyak KA; Kelfer H; Khakoo Y; Mantovani JF; Nicholson SH; Sanders JM; Wegner S
    J Pediatr Hematol Oncol; 2006 Sep; 28(9):585-93. PubMed ID: 17006265
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dexamethasone, Intravenous Immunoglobulin, and Rituximab Combination Immunotherapy for Pediatric Opsoclonus-Myoclonus Syndrome.
    Pranzatelli MR; Tate ED
    Pediatr Neurol; 2017 Aug; 73():48-56. PubMed ID: 28651977
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Treatment of neuroblastoma-related opsoclonus-myoclonus-ataxia syndrome with high-dose dexamethasone pulses.
    Ertle F; Behnisch W; Al Mulla NA; Bessisso M; Rating D; Mechtersheimer G; Hero B; Kulozik AE
    Pediatr Blood Cancer; 2008 Mar; 50(3):683-7. PubMed ID: 17226843
    [TBL] [Abstract][Full Text] [Related]  

  • 11. [Opsoclonus myoclonus ataxia syndrome in Israel].
    Blumkin L; Lerman-Sagie T
    Harefuah; 2010 Jan; 149(1):24-8, 63. PubMed ID: 20422836
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Active comparator-controlled, rater-blinded study of corticotropin-based immunotherapies for opsoclonus-myoclonus syndrome.
    Tate ED; Pranzatelli MR; Verhulst SJ; Markwell SJ; Franz DN; Graf WD; Joseph SA; Khakoo YN; Lo WD; Mitchell WG; Sivaswamy L
    J Child Neurol; 2012 Jul; 27(7):875-84. PubMed ID: 22378659
    [TBL] [Abstract][Full Text] [Related]  

  • 13. B cell depletion therapy for new-onset opsoclonus-myoclonus.
    Pranzatelli MR; Tate ED; Swan JA; Travelstead AL; Colliver JA; Verhulst SJ; Crosley CJ; Graf WD; Joseph SA; Kelfer HM; Raju GP
    Mov Disord; 2010 Jan; 25(2):238-42. PubMed ID: 20063398
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic down-regulation of central and peripheral B-cell-activating factor (BAFF) production in pediatric opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Hoefgen ER; Swan JA; Colliver JA
    Cytokine; 2008 Oct; 44(1):26-32. PubMed ID: 18675552
    [TBL] [Abstract][Full Text] [Related]  

  • 15. CSF neurofilament light chain is elevated in OMS (decreasing with immunotherapy) and other pediatric neuroinflammatory disorders.
    Pranzatelli MR; Tate ED; McGee NR; Verhulst SJ
    J Neuroimmunol; 2014 Jan; 266(1-2):75-81. PubMed ID: 24342231
    [TBL] [Abstract][Full Text] [Related]  

  • 16. High dose pulsatile dexamethasone therapy in children with opsoclonus-myoclonus syndrome.
    Rostásy K; Wilken B; Baumann M; Müller-Deile K; Bieber I; Gärtner J; Möller P; Angelini P; Hero B
    Neuropediatrics; 2006 Oct; 37(5):291-5. PubMed ID: 17236108
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Chemokine/cytokine profiling after rituximab: reciprocal expression of BCA-1/CXCL13 and BAFF in childhood OMS.
    Pranzatelli MR; Tate ED; Travelstead AL; Verhulst SJ
    Cytokine; 2011 Mar; 53(3):384-9. PubMed ID: 21211990
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Opsoclonus-ataxia caused by childhood neuroblastoma: developmental and neurologic sequelae.
    Mitchell WG; Davalos-Gonzalez Y; Brumm VL; Aller SK; Burger E; Turkel SB; Borchert MS; Hollar S; Padilla S
    Pediatrics; 2002 Jan; 109(1):86-98. PubMed ID: 11773546
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pediatric dosing of rituximab revisited: serum concentrations in opsoclonus-myoclonus syndrome.
    Pranzatelli MR; Tate ED; Verhulst SJ; Bertolone SJ; Bhatla D; Granger M; Lebowizc J; Lockhart SK; Wiley JM
    J Pediatr Hematol Oncol; 2010 Jul; 32(5):e167-72. PubMed ID: 20606544
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Ofatumumab for a rituximab-allergic child with chronic-relapsing paraneoplastic opsoclonus-myoclonus.
    Pranzatelli MR; Tate ED; Shenoy S; Travelstead AL
    Pediatr Blood Cancer; 2012 Jun; 58(6):988-91. PubMed ID: 21618414
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.